Publication Errata

Important Correction Notice - Demystifying Drug Dosing in Obese Patients

The American Society for Health-System Pharmacists (ASHP) has issued an important correction notice for Demystifying Drug Dosing in Obese Patients by Brandon R. Shank and David E. Zimmerman.

On page 84, Chapter 4, Critical Care, under the heading "Ibutilide" in the published book, dosing appears as "10 mg (one vial)."

The corrected version of the paragraph is as follows:

Ibutilide is a Vaughan-Williams Class III antiarrhythmic indicated for the rapid conversion of atrial fibrillation or atrial flutter.35 The dosing for ibutilide recommends 1 mg IV infusion over 10 minutes for patients who weigh 60 kg or more.35 A second infusion of 1 mg can be given 10 minutes later if the arrhythmias did not terminate. No other data are available for dosing in obese patients, and the above dosing of 1 mg should be used.

For print copy purchasers:

If you have a print copy of Demystifying Drug Dosing in Obese Patients, please return the copy to ASHP. ASHP will send you a corrected copy at no charge. For shipping the book to ASHP, please call 866-279-0681 or email ASHP at [email protected] for a prepaid shipping label.

For ebook purchasers:

Please delete your current ebook file for this title. To receive a corrected ebook file, go to your ebook library at If you have any questions, please contact ASHP

More News

Since the 2021-2022 influenza (flu) vaccine became available in September, the Institute for Safe Medication Practices (ISMP) has received multiple reports of mix-ups. Some patients have consented to a flu vaccine but received one of the COVID-19 vaccines instead, while others have received the flue